Trial reportCell biochemistry and biophysics2025
DNA Receptor Toll-Like Receptor 9 Signaling Pathway Plays a Major Immunomodulatory Role in Neonatal Acute Lung Injury by Inhibiting Inflammatory Response and Oxidative Stress.
Trial report in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the clinical efficacy of neonatal acute lung injury (NALI) and the mechanistic role of the DNA sensor Toll-like receptor 9 (TLR9) signaling pathway in treatment, Methods: This study enrolled 76 cases of NALI, randomly divided into 38 cases in the experimental group (intravenous injection of human immunoglobulin on the basis of nasal continuous positive airway pressure ventilation treatment) and 38 cases in the control group (nasal continuous positive airway pressure ventilation treatment). The pulmonary function parameters (forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and FEV1/FVC), TLR9 signaling pathway-related proteins and mRNA levels (TLR9, MyD88, p38), inflammatory factors (C-reactive protein (CRP), interleukin (IL)-1β, tumor necrosis factor (TNF)-α), and immune function indicators (immunoglobulin (Ig)A, IgG, IgM) were compared between the two groups. Pearson correlation analysis was conducted to examine the relationship between TLR9 signaling pathway protein expression and immune function indicators.After treatment, the pulmonary function parameters FVC, FEV1, and FEV1/FVC in neonates in the experimental group were considerably higher than those in the control group (P < 0.05). The serum levels of inflammatory factors CRP, IL-1β, and TNF-α in the experimental group of neonates following treatment were significantly lower than those in the control group (P < 0.05). After treatment, the levels of immune function indicators IgA, IgG, and IgM in neonates in the experimental group were considerably lower than those in the control group (P < 0.05). The protein expression levels of TLR9 showed a highly significant positive correlation with neonatal immune function indicators IgA, IgG, and IgM levels (P < 0.001). MyD88 protein expression exhibited a significant positive correlation with neonatal immune function indicators IgA, IgG, and IgM levels (P < 0.05). p38 protein expression demonstrated a significant positive correlation with neonatal immune function indicators IgA, IgG, and IgM levels (P < 0.05). In summary, the potential role of DNA receptor TLR9 signaling pathway-related proteins in the treatment of neonates with lung injury has been explored. The changes in the expression levels of TLR9/MyD88/p38 are associated with the production or regulation of immunoglobulins, and this association shows a certain correlation with the clinical efficacy in neonates with lung injury.
Indexed as
Identifiers
40053211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.